My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed · Phase 2

Conditions studied: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer

In brief

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Key facts

Study ID
NCT02091141
Run by
Genentech, Inc.
People needed
673
Starts
2014-04-14
Expected to finish
2023-05-24
Last updated by the study team
2024-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.